Brief: Candel Therapeutics Reports Encouraging Initial Survival Data From Phase 2 Clinical Trial Of Can-2409 In Non-Small Cell Lung Cancer

Candel Therapeutics

26/09/2023 13:04

Sept 26 (Reuters) - Candel Therapeutics Inc  CADL.O :
    * CANDEL THERAPEUTICS REPORTS ENCOURAGING INITIAL SURVIVAL
DATA
FROM PHASE 2 CLINICAL TRIAL OF CAN-2409 IN NON-SMALL CELL LUNG
CANCER
    * CANDEL THERAPEUTICS INC -  TOPLINE OVERALL SURVIVAL DATA
EXPECTED IN Q2 2024
    * CANDEL THERAPEUTICS REPORTS ENCOURAGING INITIAL SURVIVAL
DATA
FROM PHASE 2 CLINICAL TRIAL OF CAN-2409 IN NON-SMALL CELL LUNG
CANCER
    * CANDEL THERAPEUTICS INC - INITIAL DATA SUGGESTS 12-MONTH
SURVIVAL IS CONSISTENT WITH AN INCREASED TAIL ON MATURING
SURVIVAL CURVE

Source text for Eikon:  ID:nGNXbTfLFP 
Further company coverage:  CADL.O 

 ((Reuters.Briefs@thomsonreuters.com;))